<p>Prime Medicine, Inc.（纽约证券交易所代码：PRME - 获取免费报告）在周三的交易中上涨了 7.3%。该公司的股价最高达到 4.51 美元，最后交易价为 4.4650 美元。在午盘交易中，共交易了 1,509,973 股，较平均交易量 3,151,651 股下降了 52%。该股票此前收盘价为 4.16 美元。</p>
<p>获取 <strong>Prime Medicine</strong> 的提醒：</p>
<h2>分析师升级和降级</h2>
<ul>
<li>2024 年值得关注的 2 只基因编辑股票</li>
</ul>
<p>多位股票分析师对 PRME 股票发表了看法。Lifesci Capital 在 12 月 23 日的研究报告中开始覆盖 Prime Medicine。他们对该股票给予了 “跑赢大盘” 的评级，并设定了 6.00 美元的目标价。花旗集团在 11 月 11 日的报告中将 Prime Medicine 的目标价从 5.00 美元下调至 4.25 美元，并对该股票设定了 “中性” 评级。Chardan Capital 在 11 月 10 日的报告中将 Prime Medicine 的目标价从 10.00 美元下调至 9.00 美元，并对该公司给予了 “买入” 评级。最后，Wedbush 在 11 月 10 日的报告中重申了 “跑赢大盘” 的评级，并对 Prime Medicine 的股票设定了 8.00 美元的目标价。四位研究分析师对该股票给予了 “买入” 评级，三位分析师对该公司给予了 “持有” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，共识目标价为 7.21 美元。</p>
<p><strong>获取我们关于 PRME 的最新报告</strong></p>
<h2>Prime Medicine 价格表现</h2>
<p>该公司的 50 日移动平均价格为 3.77 美元，200 日移动平均价格为 4.19 美元。该股票的市值为 7.9154 亿美元，市盈率为-2.16，贝塔值为 2.71。</p>
<h2>机构资金流入和流出</h2>
<p>几家大型投资者最近买入和卖出了该股票的股份。拉塞尔投资集团在第三季度将其在 Prime Medicine 的持股增加了 1,316.4%。拉塞尔投资集团现在拥有 6,827 股该公司的股票，价值 38,000 美元，此前在该期间内又购买了 6,345 股。琼斯金融公司在第三季度收购了 Prime Medicine 的新股份，价值约 49,000 美元。斯特林投资顾问在第三季度购买了 Prime Medicine 的新股份，价值约 55,000 美元。Creative Planning 在第二季度收购了 Prime Medicine 的新股份，价值约 25,000 美元。最后，胜利资本管理公司在第三季度收购了 Prime Medicine 的新股份，价值约 56,000 美元。70.37% 的股票由机构投资者持有。</p>
<h2>Prime Medicine 公司简介</h2>
<p>（获取免费报告）</p>
<p>Prime Medicine, Inc.（纽约证券交易所代码：PRME）是一家临床阶段的基因治疗公司，专注于利用先进的 CRISPR 衍生基因编辑技术——原编辑的潜力。通过完善精确修正致病突变所需的工具，Prime Medicine 旨在开发针对疾病潜在遗传驱动因素的单剂量治疗。该公司应用其专有的工程和递送平台，以优化靶向效率并最小化非靶向效应，使其在下一代基因编辑治疗领域处于领先地位。</p>
<p>Prime Medicine 的研发工作涵盖多个治疗领域，包括罕见遗传疾病、免疫肿瘤学和自身免疫疾病。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Prime Medicine</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
<li>如果你在美国银行账户中存现金……请立即阅读</li>
<li>将这些代码输入你的普通经纪账户</li>
<li>这个 AI 机会是为了随着需求而发展而建立的</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
<p><em>此即时新闻提醒是通过叙述科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Prime Medicine 吗？</h2>
<p>在你考虑 Prime Medicine 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Prime Medicine 并不在名单上。</p>
<p>虽然 Prime Medicine 目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRME

<p>Prime Medicine (NYSE:PRME) 的股价上涨了 7.3%，达到 4.4650 美元，尽管交易量下降了 52%。分析师们的看法不一：Lifesci Capital 给予 “跑赢大盘” 的评级，目标价为 6.00 美元，而花旗集团将目标价下调至 4.25 美元，评级为 “中性”。Chardan Capital 将目标价下调至 9.00 美元，评级为 “买入”，而 Wedbush 维持 “跑赢大盘” 的评级，目标价为 8.00 美元。该股票的市值为 7.9154 亿美元，主要由机构投资者持有（70.37%）</p>

<p>Shares of Prime Medicine, Inc. (NYSE:PRME - Get Free Report) traded up 7.3% during trading on Wednesday . The company traded as high as $4.51 and last traded at $4.4650. 1,509,973 shares were traded during mid-day trading, a decline of 52% from the average session volume of 3,151,651 shares. The stock had previously closed at $4.16.</p>
<div class="lb-trans"><p>Prime Medicine, Inc.（纽约证券交易所代码：PRME - 获取免费报告）在周三的交易中上涨了 7.3%。该公司的股价最高达到 4.51 美元，最后交易价为 4.4650 美元。在午盘交易中，共交易了 1,509,973 股，较平均交易量 3,151,651 股下降了 52%。该股票此前收盘价为 4.16 美元。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Prime Medicine</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><ul>
<li>2 gene editing stocks to keep on your 2024 watchlist</li>
</ul>
<div class="lb-trans"><ul>
<li>2024 年值得关注的 2 只基因编辑股票</li>
</ul>
</div><p>A number of equities analysts have weighed in on PRME shares. Lifesci Capital initiated coverage on Prime Medicine in a research report on Tuesday, December 23rd. They set an &#34;outperform&#34; rating and a $6.00 price target on the stock. Citigroup decreased their target price on Prime Medicine from $5.00 to $4.25 and set a &#34;neutral&#34; rating on the stock in a report on Tuesday, November 11th. Chardan Capital cut their price target on Prime Medicine from $10.00 to $9.00 and set a &#34;buy&#34; rating for the company in a report on Monday, November 10th. Finally, Wedbush reiterated an &#34;outperform&#34; rating and issued a $8.00 price objective on shares of Prime Medicine in a report on Monday, November 10th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $7.21.</p>
<div class="lb-trans"><p>多位股票分析师对 PRME 股票发表了看法。Lifesci Capital 在 12 月 23 日的研究报告中开始覆盖 Prime Medicine。他们对该股票给予了 “跑赢大盘” 的评级，并设定了 6.00 美元的目标价。花旗集团在 11 月 11 日的报告中将 Prime Medicine 的目标价从 5.00 美元下调至 4.25 美元，并对该股票设定了 “中性” 评级。Chardan Capital 在 11 月 10 日的报告中将 Prime Medicine 的目标价从 10.00 美元下调至 9.00 美元，并对该公司给予了 “买入” 评级。最后，Wedbush 在 11 月 10 日的报告中重申了 “跑赢大盘” 的评级，并对 Prime Medicine 的股票设定了 8.00 美元的目标价。四位研究分析师对该股票给予了 “买入” 评级，三位分析师对该公司给予了 “持有” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，共识目标价为 7.21 美元。</p>
</div><p><strong>Get Our Latest Report on PRME</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 PRME 的最新报告</strong></p>
</div><h2>Prime Medicine Price Performance</h2>
<div class="lb-trans"><h2>Prime Medicine 价格表现</h2>
</div><p>The business's fifty day moving average price is $3.77 and its 200 day moving average price is $4.19. The stock has a market cap of $791.54 million, a P/E ratio of -2.16 and a beta of 2.71.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 3.77 美元，200 日移动平均价格为 4.19 美元。该股票的市值为 7.9154 亿美元，市盈率为-2.16，贝塔值为 2.71。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. increased its position in shares of Prime Medicine by 1,316.4% during the third quarter. Russell Investments Group Ltd. now owns 6,827 shares of the company's stock worth $38,000 after buying an additional 6,345 shares during the period. Jones Financial Companies Lllp acquired a new stake in Prime Medicine during the 3rd quarter worth about $49,000. Sterling Investment Advisors Ltd. bought a new position in shares of Prime Medicine in the 3rd quarter worth about $55,000. Creative Planning acquired a new position in shares of Prime Medicine in the 2nd quarter valued at about $25,000. Finally, Victory Capital Management Inc. bought a new stake in shares of Prime Medicine during the 3rd quarter valued at about $56,000. 70.37% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家大型投资者最近买入和卖出了该股票的股份。拉塞尔投资集团在第三季度将其在 Prime Medicine 的持股增加了 1,316.4%。拉塞尔投资集团现在拥有 6,827 股该公司的股票，价值 38,000 美元，此前在该期间内又购买了 6,345 股。琼斯金融公司在第三季度收购了 Prime Medicine 的新股份，价值约 49,000 美元。斯特林投资顾问在第三季度购买了 Prime Medicine 的新股份，价值约 55,000 美元。Creative Planning 在第二季度收购了 Prime Medicine 的新股份，价值约 25,000 美元。最后，胜利资本管理公司在第三季度收购了 Prime Medicine 的新股份，价值约 56,000 美元。70.37% 的股票由机构投资者持有。</p>
</div><h2>Prime Medicine Company Profile</h2>
<div class="lb-trans"><h2>Prime Medicine 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Prime Medicine, Inc NYSE: PRME is a clinical-stage genetic medicines company focused on harnessing the potential of prime editing, an advanced CRISPR-derived gene editing technology. By refining the tools required for precise correction of disease-causing mutations, Prime Medicine aims to develop single-dose treatments that address underlying genetic drivers of disease. The company applies its proprietary engineering and delivery platforms to optimize on-target efficiency and minimize off-target effects, positioning itself at the forefront of next-generation gene editing therapeutics.</p>
<div class="lb-trans"><p>Prime Medicine, Inc.（纽约证券交易所代码：PRME）是一家临床阶段的基因治疗公司，专注于利用先进的 CRISPR 衍生基因编辑技术——原编辑的潜力。通过完善精确修正致病突变所需的工具，Prime Medicine 旨在开发针对疾病潜在遗传驱动因素的单剂量治疗。该公司应用其专有的工程和递送平台，以优化靶向效率并最小化非靶向效应，使其在下一代基因编辑治疗领域处于领先地位。</p>
</div><p>Prime Medicine's research and development efforts span multiple therapeutic areas, including rare genetic disorders, immuno-oncology, and autoimmune diseases.</p>
<div class="lb-trans"><p>Prime Medicine 的研发工作涵盖多个治疗领域，包括罕见遗传疾病、免疫肿瘤学和自身免疫疾病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
<li>Punch these codes into your ordinary brokerage account</li>
<li>This AI Opportunity Was Built to Evolve With Demand</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Prime Medicine</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
<li>如果你在美国银行账户中存现金……请立即阅读</li>
<li>将这些代码输入你的普通经纪账户</li>
<li>这个 AI 机会是为了随着需求而发展而建立的</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是通过叙述科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Prime Medicine 吗？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Prime Medicine 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Prime Medicine 并不在名单上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Prime Medicine 目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Prime Medicine (NYSE:PRME) 的股价上涨了 7.3% - 以下是原因